German-based Bayer has selected Finnish drug development company DelSiTech as its technology partner for ophthalmology drug delivery.

The companies have signed a collaboration and technology licence agreement, under which DelSiTech’s Silica Matrix drug delivery platform will be used for Bayer’s compounds in ophthalmology.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

As per the agreement, DelSiTech will receive a number of undisclosed milestone payments after successful completion of different stages of drug development.

The company will also be entitled to receive milestone payments and royalties gained by the commercialisation and sale of the products.

"This agreement will support our work on innovative treatment options for a range of different eye diseases."

Bayer will bear all development and commercialisation expense incurred during the collaborative project.

See Also:

Bayer pharmaceuticals division executive committee member and drug discovery head professor Andreas Busch said: “Successful ocular drug delivery is one of the biggest challenges in developing novel drug therapies for ophthalmic diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This agreement will support our work on innovative treatment options for a range of different eye diseases.

“This partnership with DelSiTech underlines Bayer’s continued commitment to leverage collaborations on cutting edge science in ophthalmology with the aim to improve the quality of life for patients.”

DelSiTech Silica Matrix has been developed as an aqueous solution by the polymerisation of alkoxysilanes, Si(OR)4, using a technique called the sol-gel process.

It is also porous and contains different OH groups and water.